Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery diseaseP.M. Burger, Jeroen Schaap, Stefan M. Nidorf et al.|European Journal of Preventive Cardiology|2023Cited by 16
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-ITP.M. Burger, Deepak L. Bhatt, Jannick A N Dorresteijn et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2024Cited by 5
Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-ITP.M. Burger, Frank L.J. Visseren, Deepak L. Bhatt et al.|European Heart Journal|2023Cited by 0